Sure, there was some drama along the way with Bristol-Myers Squibb's proposed acquisition of Celgene. But it never made sense to bet against the deal. And now shareholders of both companies have approved the transaction. The only things left are the standard regulatory approvals and closing formalities.
Trending:
Why Celgene shareholders should hold on to their Bristol-Myers Squibb stock once the acquisition closes